Zenith Drugs Limited has expanded its international footprint by registering its manufacturing plant and products in Afghanistan, resulting in the receipt of its first export orders worth ₹2.50 Crores. This strategic move allows the pharmaceutical company to penetrate the Afghan market, leveraging its newly registered manufacturing capabilities to meet overseas demand.

The company submitted the details regarding this commercial development to the stock exchanges under Regulation 30. The filing confirms the successful completion of necessary registration procedures for both the facility and the specific product lines intended for export.

Export Order Details

The initial order book from Afghanistan stands at ₹2.50 Crores. This represents the immediate financial impact of the company's market entry strategy following the regulatory approvals obtained in the region.

Zenith Drugs Limited expanded its distribution network with the launch of a Mother Depot in Uttar Pradesh on May 25, 2026. The strategic move aims to strengthen the company's market presence and improve supply chain efficiency in the region.

The launch was conducted under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulatory framework mandates timely disclosure of material events to ensure transparency for shareholders.

Strategic Expansion

The establishment of the Mother Depot is expected to facilitate better inventory management and faster delivery times to distributors and retailers in Uttar Pradesh. This expansion aligns with the company's objective to enhance its operational footprint across key markets.

Operational Details

The new depot will serve as a central hub for storage and logistics, enabling Zenith Drugs to cater to the growing demand for its pharmaceutical products in the region. The initiative reflects the company's commitment to optimizing its distribution capabilities.